Chosen by Science’s editors as the breakthrough of the year for 2013,47 cancer immunotherapy using immune checkpoint inhibitors (especially drugs targeting the PD-1/PD-L1 axis) has raised much interest for cancer treatment over the last few years. This evidence concerns the gene CD274 and cancer.